Blood and Marrow Transplant

Non Hodgkin's Lymphoma

- Match Related Donor
- Unrelated Donor
- Autologous Donor

- Not Eligible for Full Dose Conditioning
- High Dose Chemotherapy Required
- Mycosis Fungoides/ Sézary Syndrome
- ≥ 18 Yrs

- BMT328 Phase II Allogeneic CD8 Memory T-Cells Infusion as Consolidative Tx After HCT in Leukemia & Lymphoma
  PI: Lowsky Stanford

- BMT236 Phase II MAHCT w/ T Cell Depleted Graft w/ Infusion of Conventional and Regulatory T Cells
  PI: Meyer NIH

- BMT206 Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma
  PI: Weng Stanford

- BMT206 Phase II Non-myeloablative Allogeneic Transplant Using TLI & ATG In Cutaneous T Cell Lymphoma
  PI: Weng Stanford

- CCT5001 Phase I CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/ Refractory B Cell Malignancies
  PI: Miklos Stanford
  1st Priority

- CCT5006-EXP Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/ Refractory T-plant- ineligible Aggressive NHL
  PI: Miklos Kite Pharma
  2nd Priority

- CCT5016 Managed Access Program (MAP) CTL019 in ALL or DLBCL
  PI: Miklos Sponsor: Pending

- CCT5020 Phase Ib Tisagenlecleucel in Combo w/ Ibrutinib in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
  PI: Miklos Sponsor: Pending

- BMT330 Phase II Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
  PI: Muffy Pending

- BMT310 Phase II KTE-C19 in Relapsed/ Refractory Mantle Cell Lymphoma
  PI: Miklos Kite Pharma
  PI: Miklos Vanderbilt University

- Mantle Cell Lymphoma

- Ibrutinib Resistance

- Histocompatible donor

**KEY**
- Pending
- Open for Enrollment
- Observational Study
- Link
- Optional Path
- Extension Study
- Immunotherapy
- Trial Posting
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu